Liquidia Technologies Inc (LQDA) - Total Assets
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) holds total assets worth $401.53 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check LQDA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Liquidia Technologies Inc - Total Assets Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's total assets have evolved over time, based on quarterly financial data. Check LQDA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Liquidia Technologies Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Liquidia Technologies Inc's total assets of $401.53 Million consist of 58.2% current assets and 41.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.2% |
| Accounts Receivable | $54.09 Million | 16.5% |
| Inventory | $23.80 Million | 7.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.95 Million | 0.9% |
| Goodwill | $3.90 Million | 1.2% |
Asset Composition Trend (2016–2025)
This chart illustrates how Liquidia Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Liquidia Technologies Inc (LQDA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liquidia Technologies Inc's current assets represent 58.2% of total assets in 2025, an increase from 37.1% in 2016.
- Cash Position: Cash and equivalents constituted 58.2% of total assets in 2025, up from 17.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 16.5% of total assets.
Liquidia Technologies Inc Competitors by Total Assets
Key competitors of Liquidia Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Liquidia Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 2.93 | 10.23 |
| Quick Ratio | 2.03 | 2.91 | 10.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $183.31 Million | $116.69 Million | $64.35 Million |
Liquidia Technologies Inc - Advanced Valuation Insights
This section examines the relationship between Liquidia Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 51.21 |
| Latest Market Cap to Assets Ratio | 16.77 |
| Asset Growth Rate (YoY) | 42.4% |
| Total Assets | $327.93 Million |
| Market Capitalization | $5.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Liquidia Technologies Inc's assets at a significant premium (16.77x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Liquidia Technologies Inc's assets grew by 42.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Liquidia Technologies Inc (2016–2025)
The table below shows the annual total assets of Liquidia Technologies Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $327.93 Million | +42.39% |
| 2024-12-31 | $230.31 Million | +94.63% |
| 2023-12-31 | $118.33 Million | -8.41% |
| 2022-12-31 | $129.20 Million | +37.84% |
| 2021-12-31 | $93.73 Million | -5.83% |
| 2020-12-31 | $99.53 Million | +44.58% |
| 2019-12-31 | $68.84 Million | +39.30% |
| 2018-12-31 | $49.42 Million | +232.93% |
| 2017-12-31 | $14.84 Million | +74.91% |
| 2016-12-31 | $8.49 Million | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more